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Future analyses of my study cohort can hopefully
provide more data on the association between local and
systemic inflammation and cardiac comorbidities in
COPD.
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Background: Numerous studies have demonstrated
evidence of oxidative stress in COPD, in both respiratory
tract lining fluids and biopsies. Antioxidant response in
airway inflammatory cells to a pro-oxidative
environment is however poorly understood. We have
previously demonstrated an enhanced antioxidant
enzyme activity in macrophages from asthmatics. This
study was performed to assess whether a similar adap-
tation in intra-cellular antioxidants occurred in subjects
with COPD. The activities of enzymatic antioxidants
were examined in alveolar mixed cell populations and
compared to healthy age-matched controls (ACs) and
young adults, to permit the relative contributions of
disease state and natural ageing to be disentangled.
Methods: Airway leukocytes were obtained by bronchos-
copy-based lavage and cellular activities of Cu,Zn
superoxide dismutase (SOD1), glutathione peroxidase
(GPx), catalase (CAT) and glutathione reductase (GSSG-
red) were determined. In addition, cellular glutathione
and glutathione disulphide concentrations were
quantified to determine cellular redox status.
Results: No differences in the activity of the major
enzymatic antioxidants or intra-cellular GSH concen-
tration were observed between COPD patients and ACs.
In contrast, significantly reduced SOD1 (p<0.001), GPx
(p=0.04) and GSSG-red (p=0.01) activities were
observed in the ACs relative to the young adult group. In
contrast, catalase activity was elevated in the ACs
(p=0.001), but again with no further enhancement in
the COPD group.
Conclusion: These data demonstrate a loss of adaptive
plasticity associated with ageing, rather than a COPD-
specific down regulation of antioxidant defences. These
data do however highlight that in COPD, unlike asthma,
the imposition of oxidative stress does not induce
protective adaptations, implying a greater sensitivity to
oxidant injury in vivo.
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Nerve growth factor (NGF) and neurotrophin-3 (NT-3)
belong to the neurotrophin family and are important
growth- and survival factors for neurons. Lately, they
have also been shown to be potent inflammatory
mediators as well as factors promoting tissue repair
processes. Increased levels of neurotrophins have
previously been shown in the airways of patients with
asthma and sarcoidosis.
In this study we investigated the levels of neuro-
trophins in the airways of patients with moderate to
severe COPD (n=25), healthy non-smokers (n=12) and
asymptomatic smokers (n=16). We found decreased
levels of NGF and NT-3 in bronchoalveolar lavage fluid
(BALF) in COPD patients and asymptomatic smokers as
compared to healthy non-smokers. These findings
suggest that smoking per se decreases the release of
neurotrophins in the airways. Structural cells, such as
epithelial cells and fibroblasts, are known sources of
neurotrophins. We found that NGF secretion was
decreased from cultured human lung fibroblasts
exposed to cigarette smoke extract.
These results indicate that smoking have inhibitory
effects on neurotrophin secretion in the airways. The
functional consequence of lower levels of neurotrophins
in the airways of smokers and COPD patients is still
unknown and further studies are required to elucidate
the role of neurotrophins in inflammatory pulmonary
diseases.
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Chronic airway inflammation is a key feature in the
pathogenesis of COPD, and inhaled corticosteroids (ICS)
are widely used to alleviate airway inflammation in
COPD. We tested if non-invasive markers of airway
inflammation are related to lung function in COPD, or if
these markers can predict responsiveness to ICS.
S4 M. Sköld et al.
